A medium-throughput screen for inhibitors of human metapneumovirus
- PMID: 30759993
- PMCID: PMC6376503
- DOI: 10.1177/2040206619830197
A medium-throughput screen for inhibitors of human metapneumovirus
Abstract
Human metapneumovirus, a paramyxovirus discovered in 2001, is a major cause of lower respiratory infection in adults and children worldwide. There are no licensed vaccines or drugs for human metapneumovirus. We developed a fluorescent, cell-based medium-throughput screening assay for human metapneumovirus that captures inhibitors of all stages of the viral lifecycle except budding of progeny virus particles from the cell membrane. We optimized and validated the assay and performed a successful medium-throughput screening. A number of hits were identified, several of which were confirmed to inhibit viral replication in secondary assays. This assay offers potential to discover new antivirals for human metapneumovirus and related respiratory viruses. Compounds discovered using the medium-throughput screening may also provide useful probes of viral biology.
Keywords: Human metapneumovirus; high-throughput screen; paramyxovirus; statins; topoisomerase inhibitors.
Figures





Similar articles
-
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays.Antiviral Res. 2004 Jul;63(1):51-9. doi: 10.1016/j.antiviral.2004.02.006. Antiviral Res. 2004. PMID: 15196820
-
Synthetic sulfonated derivatives of poly(allylamine hydrochloride) as inhibitors of human metapneumovirus.PLoS One. 2019 Mar 28;14(3):e0214646. doi: 10.1371/journal.pone.0214646. eCollection 2019. PLoS One. 2019. PMID: 30921418 Free PMC article.
-
Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.Antiviral Res. 2017 Feb;138:47-56. doi: 10.1016/j.antiviral.2016.11.018. Epub 2016 Dec 3. Antiviral Res. 2017. PMID: 27919709
-
Screening methods for influenza antiviral drug discovery.Expert Opin Drug Discov. 2012 May;7(5):429-38. doi: 10.1517/17460441.2012.674510. Epub 2012 Mar 22. Expert Opin Drug Discov. 2012. PMID: 22435452 Review.
-
Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.Virulence. 2017 Aug 18;8(6):685-704. doi: 10.1080/21505594.2016.1265725. Epub 2016 Dec 2. Virulence. 2017. PMID: 27911218 Free PMC article. Review.
Cited by
-
Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection.Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0100822. doi: 10.1128/aac.01008-22. Epub 2022 Sep 12. Antimicrob Agents Chemother. 2022. PMID: 36094205 Free PMC article.
-
Human Metapneumovirus: A Largely Unrecognized Threat to Human Health.Pathogens. 2020 Feb 13;9(2):109. doi: 10.3390/pathogens9020109. Pathogens. 2020. PMID: 32069879 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources